Should our selection for neoadjuvant chemotherapy in ovarian cancer patients change in light of COVID-19?  

I see this as a two-pronged question where the response may vary based on the specific clinical situation, circumstances of the hospital, and status of the epidemic locally and regionally, along with available resources associated with the rapidly evolving COVID-19 pandemic. There is no question pr...